ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will ...
Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...
(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
A phase II study of preoperative docetaxel, cisplatin, and capecitabine in patients with gastric carcinoma. Background: ABI-007 is a novel Cremophor-free nanoparticle albumin-bound paclitaxel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback